Trials / Available
AvailableNCT03723148
Individual Patient Compassionate Use of Fedratinib
Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib. Expanded access is only available in markets where fedratinib is not yet approved.
Detailed description
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral Fedratinib | Oral fedratinib administered as directed by treating physician. |
Timeline
- First posted
- 2018-10-29
- Last updated
- 2020-09-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03723148. Inclusion in this directory is not an endorsement.